The active ingredient in Ozempic was associated with a reduced risk of Alzheimer's disease-related dementia among diabetes ...

A new clinical trial found that taking a popular diabetes and weight-loss drug once weekly significantly improves blood sugar ...

AUSTIN, Texas, June 12, 2025--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a leader in AI-powered drug discovery and biotherapeutics, today announced compelling in vitro results demonstrating that ...

AUSTIN, Texas — ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a leader in AI-powered drug discovery and biotherapeutics, today announced compelling in vitro results demonstrating that its artificial ...

Semaglutide belongs to a class of medications called glucagon-like peptide-1 receptor agonists, or GLP-1s. These prescription drugs mimic the GLP-1 hormone, which is made naturally in the gut ...

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of patients and offering new hope for those with the life-threatening condition.

Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis. New England Journal of Medicine , 2025; DOI: 10.1056/NEJMoa2413258 Cite This Page : ...

A semaglutide group of 174,584 patients (51.8% women, 41.1% men) was compared with a control group of 174,584 patients (51.82% women, 41.24% men) that received non-glucagonlike peptide 1 receptor ...

Semaglutide is the active ingredient in certain brand-name medications prescribed for obesity, type 2 diabetes, and more. Semaglutide belongs to the glucagon-like peptide-1 (GLP-1) receptor ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, ... Semaglutide is in a class called glucagon-like peptide-1 (GLP-1) receptor agonists.

Some of the most common peptides for weight loss are glucagon-like peptide 1 (GLP-1) receptor agonists. They include semaglutide (Wegovy), liraglutide (Saxenda), and tirzepatide (Zepbound).